Literature DB >> 30610652

Therapeutic Effect of Agmatine on Neurological Disease: Focus on Ion Channels and Receptors.

Sumit Barua1, Jong Youl Kim1, Jae Young Kim1, Jae Hwan Kim2, Jong Eun Lee3,4,5.   

Abstract

The central nervous system (CNS) is the most injury-prone part of the mammalian body. Any acute or chronic, central or peripheral neurological disorder is related to abnormal biochemical and electrical signals in the brain cells. As a result, ion channels and receptors that are abundant in the nervous system and control the electrical and biochemical environment of the CNS play a vital role in neurological disease. The N-methyl-D-aspartate receptor, 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl) propanoic acid receptor, kainate receptor, acetylcholine receptor, serotonin receptor, α2-adrenoreceptor, and acid-sensing ion channels are among the major channels and receptors known to be key components of pathophysiological events in the CNS. The primary amine agmatine, a neuromodulator synthesized in the brain by decarboxylation of L-arginine, can regulate ion channel cascades and receptors that are related to the major CNS disorders. In our previous studies, we established that agmatine was related to the regulation of cell differentiation, nitric oxide synthesis, and murine brain endothelial cell migration, relief of chronic pain, cerebral edema, and apoptotic cell death in experimental CNS disorders. In this review, we will focus on the pathophysiological aspects of the neurological disorders regulated by these ion channels and receptors, and their interaction with agmatine in CNS injury.

Entities:  

Keywords:  Agmatine; Ion channels; Neurodegenerative disease; Receptor blockade; Receptors

Mesh:

Substances:

Year:  2019        PMID: 30610652     DOI: 10.1007/s11064-018-02712-1

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  7 in total

1.  Retinoprotective effect of agmatine in streptozotocin-induced diabetic rat model: avenues for vascular and neuronal protection : Agmatine in diabetic retinopathy.

Authors:  Rehab E Abo El Gheit; Nema A Soliman; Ghada A Badawi; Nermin M Madi; Mervat H El-Saka; Shimaa M Badr; Marwa N Emam
Journal:  J Physiol Biochem       Date:  2021-02-26       Impact factor: 4.158

Review 2.  Interplay of gut microbiota and oxidative stress: Perspective on neurodegeneration and neuroprotection.

Authors:  Shruti Shandilya; Sandeep Kumar; Niraj Kumar Jha; Kavindra Kumar Kesari; Janne Ruokolainen
Journal:  J Adv Res       Date:  2021-09-17       Impact factor: 12.822

3.  Insights into the Mn2+ Binding Site in the Agmatinase-Like Protein (ALP): A Critical Enzyme for the Regulation of Agmatine Levels in Mammals.

Authors:  María-Belen Reyes; José Martínez-Oyanedel; Camila Navarrete; Erika Mardones; Ignacio Martínez; Mónica Salas; Vasthi López; María García-Robles; Estefania Tarifeño-Saldivia; Maximiliano Figueroa; David García; Elena Uribe
Journal:  Int J Mol Sci       Date:  2020-06-10       Impact factor: 5.923

4.  Structure of the E. coli agmatinase, SPEB.

Authors:  Iva Chitrakar; Syed Fardin Ahmed; Andrew T Torelli; Jarrod B French
Journal:  PLoS One       Date:  2021-04-15       Impact factor: 3.240

5.  Maintenance of the Neuroprotective Function of the Amino Group Blocked Fluorescence-Agmatine.

Authors:  Sumit Barua; A Young Sim; Jong Youl Kim; Injae Shin; Jong Eun Lee
Journal:  Neurochem Res       Date:  2021-04-29       Impact factor: 3.996

6.  Effects of imidazoline agents in a rat conditioned place preference model of addiction.

Authors:  V Şorodoc; G Rusu-Zota; P Nechita; C Moraru; O M Manole
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-01-08       Impact factor: 3.000

Review 7.  New Insights Into the Pivotal Role of CREB-Regulated Transcription Coactivator 1 in Depression and Comorbid Obesity.

Authors:  Clara Rossetti; Antoine Cherix; Laetitia F Guiraud; Jean-René Cardinaux
Journal:  Front Mol Neurosci       Date:  2022-02-15       Impact factor: 5.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.